Regenxbio (RGNX) Reports Q2 EPS of $0.30; Announces Positive Interim Update from RGX-314 Phase I Clinical Trial for Wet AMD

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. MU
8. PFE
9. AWK
10. ACN

Go back to Regenxbio (RGNX) Reports Q2 EPS of $0.30; Announces Positive Interim Update from RGX-314 Phase I Clinical Trial for Wet AMD

Regenxbio Inc. (RGNX) PT Lowered to $127.50 at Chardan Capital Markets; Sees Low Bar in Wet AMD

August 8, 2018 12:20 PM EDT

Chardan Capital Markets lowered its price target on Regenxbio Inc. (NASDAQ: RGNX) to $127.50 (from $130.00) while maintaining a Buy rating following positive interim data from its phase I study of RGX-314 in wet AMD (NCT03066258) and to us negative interim data in... More